Investors
A category-defining bet on pre-emptive care.
Anthogen is building the operating system for at-home chronic disease management — and the data layer that makes it pay.
A one-minute overview of Anthogen.
$412B
Global digital therapeutics market by 2032
133M
U.S. adults living with at least one chronic condition
6 modules
ARTA condition modules in development
Why now
A reimbursement-driven system at its limits.
Demand for healthcare from an aging population is rising sharply, just as clinicians leave the field. Anthogen reduces the burden of chronic disease by changing daily behavior — at a fraction of the cost of acute care. The result is better outcomes, lower spend, and a durable software business sitting between patient and payer.
Investment thesis
Three structural tailwinds.
Reimbursement is here
CMS and major payers now reimburse remote therapeutic monitoring (CPT 98975–98981). Anthogen's modules are designed around these codes from day one.
Capital-efficient distribution
We sell to health systems and self-insured employers — channels with concentrated decision-making and recurring per-patient economics.
Defensible data moat
Each ARTA module compounds a behavioral dataset that improves personalization — and is impossible to retroactively assemble.
Traction
Real patients. Real outcomes. Real revenue.
1,000+
Patients enrolled across active CardiFit pilots
12
Health system partners under LOI or contract
$4.2M
ARR run-rate as of Q1 2026
89%
Average program adherence
The round
Series A — open through Q3 2026.
We are raising to expand CardiFit into 50 health systems, complete the JointFit and DiabFit module launches, and grow our clinical evidence base.
Round size
$22M
Lead
Confirmed — name on request
Use of funds
Commercial expansion · clinical evidence · platform
Closing
Q3 2026
FAQ
Investor questions, answered.
- What stage is Anthogen at?
- Anthogen is a commercial-stage digital therapeutics company. CardiFit is live across multiple health-system pilots with a $4.2M ARR run-rate as of Q1 2026, and we are raising a $22M Series A to scale. Request investor materials
- How does Anthogen generate revenue?
- Anthogen sells per-patient subscriptions to health systems and self-insured employers. Our modules are designed around reimbursable CPT codes (including 93798/93799 and 98975–98981), creating recurring economics with concentrated decision-makers. Request investor materials
- What is the size of the Series A round?
- We are raising $22M to expand CardiFit into 50 health systems, complete the JointFit and DiabFit module launches, and grow our clinical evidence base. The round is led and closing in Q3 2026. Request investor materials
- How can I request the data room?
- Reach the team at investors@anthogen.com or use the investor materials request form. We typically share the data room after an introductory call with leadership. Request investor materials
Want to dig deeper?
Request the data room and a meeting with the leadership team.
Request investor materials